Skip to main content

Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.

Publication ,  Journal Article
Gandhi, UH; Cornell, RF; Lakshman, A; Gahvari, ZJ; McGehee, E; Jagosky, MH; Gupta, R; Varnado, W; Fiala, MA; Chhabra, S; Malek, E; Mansour, J ...
Published in: Leukemia
September 2019

The introduction of CD38-targeting monoclonal antibodies (CD38 MoABs), daratumumab and isatuximab, has significantly impacted the management of patients with multiple myeloma (MM). Outcomes of patients with MM refractory to CD38 MoABs have not been described. We analyzed outcomes of 275 MM patients at 14 academic centers with disease refractory to CD38 MoABs. Median interval between MM diagnosis and refractoriness to CD38 MoAB (T0) was 50.1 months. The median overall survival (OS) from T0 for the entire cohort was 8.6 [95% C.I. 7.5-9.9] months, ranging from 11.2 months for patients not simultaneously refractory to an immunomodulatory (IMiD) agent and a proteasome inhibitor (PI) to 5.6 months for "penta-refractory" patients (refractory to CD38 MoAB, 2 PIs and 2 IMiDs). At least one subsequent treatment regimen was employed after T0 in 249 (90%) patients. Overall response rate to first regimen after T0 was 31% with median progression-free survival (PFS) and OS of 3.4 and 9.3 months, respectively. PFS was best achieved with combinations of carfilzomib and alkylator (median 5.7 months), and daratumumab and IMiD (median 4.5 months). Patients with MM refractory to CD38 MoAB have poor prognosis and this study provides benchmark for new therapies to be tested in this population.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Leukemia

DOI

EISSN

1476-5551

Publication Date

September 2019

Volume

33

Issue

9

Start / End Page

2266 / 2275

Location

England

Related Subject Headings

  • Young Adult
  • Proteasome Inhibitors
  • Progression-Free Survival
  • Multiple Myeloma
  • Middle Aged
  • Membrane Glycoproteins
  • Male
  • Immunotherapy
  • Immunology
  • Immunologic Factors
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Gandhi, U. H., Cornell, R. F., Lakshman, A., Gahvari, Z. J., McGehee, E., Jagosky, M. H., … Costa, L. J. (2019). Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia, 33(9), 2266–2275. https://doi.org/10.1038/s41375-019-0435-7
Gandhi, Ujjawal H., Robert F. Cornell, Arjun Lakshman, Zhubin J. Gahvari, Elizabeth McGehee, Megan H. Jagosky, Ridhi Gupta, et al. “Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.Leukemia 33, no. 9 (September 2019): 2266–75. https://doi.org/10.1038/s41375-019-0435-7.
Gandhi UH, Cornell RF, Lakshman A, Gahvari ZJ, McGehee E, Jagosky MH, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019 Sep;33(9):2266–75.
Gandhi, Ujjawal H., et al. “Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.Leukemia, vol. 33, no. 9, Sept. 2019, pp. 2266–75. Pubmed, doi:10.1038/s41375-019-0435-7.
Gandhi UH, Cornell RF, Lakshman A, Gahvari ZJ, McGehee E, Jagosky MH, Gupta R, Varnado W, Fiala MA, Chhabra S, Malek E, Mansour J, Paul B, Barnstead A, Kodali S, Neppalli A, Liedtke M, Narayana S, Godby KN, Kang Y, Kansagra A, Umyarova E, Scott EC, Hari P, Vij R, Usmani SZ, Callander NS, Kumar SK, Costa LJ. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019 Sep;33(9):2266–2275.

Published In

Leukemia

DOI

EISSN

1476-5551

Publication Date

September 2019

Volume

33

Issue

9

Start / End Page

2266 / 2275

Location

England

Related Subject Headings

  • Young Adult
  • Proteasome Inhibitors
  • Progression-Free Survival
  • Multiple Myeloma
  • Middle Aged
  • Membrane Glycoproteins
  • Male
  • Immunotherapy
  • Immunology
  • Immunologic Factors